A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Overview

About this study

The purpose of this study is to compare the effectiveness of JNJ-68284528 with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Be at least 18 years of age.
  • Have documented diagnosis of MM as defined by the criteria below:
    • Multiple myeloma diagnosis according to the IMWG diagnostic criteria;
    • Measurable disease at screening as defined by any of the following:
      • Serum monoclonal paraprotein (M-protein) level ≥ 1.0 gram per deciliter (g/dL) or urine M-protein level ≥ 200 milligram (mg)/24 hours; or
      • Light chain multiple myeloma without measurable M-protein in the serum or the urine: Serum free light chain ≥ 10 mg/dL and abnormal serum free light chain ratio.
  • Have received 1 to 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD).
  • Have documented evidence of PD by International Myeloma Working Group (IMWG) criteria based on investigator's determination on or within 6 months of their last regimen.
  • Be refractory to lenalidomide per IMWG consensus guidelines (failure to achieve minimal response or progression on or within 60 days of completing lenalidomide therapy). Progression on or within 60 days of the last dose of lenalidomide given as maintenance will meet this criterion. For participants with more than 1 prior line of therapy, there is no requirement to be lenalidomide refractory to the most recent line of prior therapy. However, participants must be refractory to lenalidomide in at least one prior line
  • Have clinical laboratory values meeting the following criteria during the Screening Phase (re testing is allowed but the below criteria must be met in the latest test prior to randomization):
    • Hemoglobin ≥ 8 gram per deciliter (g/dL) (without prior RBC transfusion within 7 days before the laboratory test; recombinant human erythropoietin use is permitted);
    • Absolute neutrophil count (ANC) ≥ 1 x 10^9 per liter (L) (without recombinant human granulocyte colony-stimulating factor [G-CSF] within 7 days and without pegylated G-CSF within 14 days of the laboratory test);
    • Platelet count ≥ 75 x 10^9/L (without prior platelet transfusion within 7 days before the laboratory test) in subjects in whom less than (<) 50 percent (%) of bone marrow nucleated cells are plasma cells; platelet count ≥ 50 x 10^9/L (without prior platelet transfusion within 7 days before the laboratory test) in subjects in whom ≥ 50% of bone marrow nucleated cells are plasma cells;
    • Lymphocyte count ≥ 0.3 x 10^9/L;
    • Aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN);
    • Alanine aminotransferase (ALT) ≤ 3 x ULN;
    • Total bilirubin ≤ 2.0 * ULN; except in subjects with congenital bilirubinemia, such as Gilbert syndrome (in which case direct bilirubin ≤ 1.5 x ULN is required);
    • Estimated glomerular filtration rate ≥ 40 milliliter per minute (mL/min) per 1.73 meter square (m^2) (to be calculated using the Modification of Diet in Renal Disease [MDRD] formula).

Exclusion Criteria:

  • Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy directed at any target.
  • Any previous therapy that is targeted to B-cell maturation antigen (BCMA).
  • Ongoing toxicity from previous anticancer therapy that has not resolved to baseline levels or to Grade 1 or less, except for alopecia,
  • Participants with Grade 1 peripheral neuropathy with pain or Grade 2 or higher peripheral neuropathy will not be permitted to receive pomalidomide, bortezomib, and dexamethasone (PVd) as standard therapy or bridging therapy; however, participant may receive daratumumab, pomalidomide, and dexamethasone (DPd) as standard therapy or bridging therapy.
  • Received a cumulative dose of corticosteroids equivalent to ≥ 70 mg of prednisone within the 7 days prior to randomization.
  • Monoclonal antibody treatment within 21 days.
  • Cytotoxic therapy within 14 days.
  • Proteasome inhibitor therapy within 14 days.
  • Immunomodulatory drug (IMiD) therapy within 7 days.

Eligibility last updated 11/15/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Jeremy Larsen, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Rochester, Minn.

Mayo Clinic principal investigator

Yi Lin, M.D., Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20508587

Mayo Clinic Footer